Syschem (India)

how big is Syschem (India)?

As of Jun 06, Syschem (India) Ltd has a market capitalization of 207.00 Cr, classifying it as a Micro Cap company, with recent net sales of 331.68 Cr and a net profit of 0.46 Cr. The standalone balance sheet shows shareholder's funds of 56.96 Cr and total assets of 163.08 Cr.

Market Cap: As of Jun 06, Syschem (India) Ltd has a market capitalization of 207.00 Cr, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest 4 quarters, Syschem (India) Ltd reported Net Sales of 331.68 Cr and a Net Profit of 0.46 Cr. This data is based on Standalone financials.<BR><BR>Balance Sheet Snapshot: The Standalone balance sheet for the reporting period ending Mar'24 shows Shareholder's Funds of 56.96 Cr and Total Assets of 163.08 Cr.

When is the next results date for Syschem (India)?

No Upcoming Board Meetings

Who are in the management team of Syschem (India)?

As of March 2023, the management team of Syschem (India) includes Ranjan Jain (Executive Director & Managing Director), Suninder Veer Singh (Executive Director & Wholetime Director), Arshdeep Kaur (Independent Non-Executive Director), Neena Batra (Non-Executive & Non-Independent Director), and Renu Rawat (Independent Non-Executive Director).

As of March 2023, the management team of Syschem (India) includes the following individuals:<BR><BR>1. Ranjan Jain - Executive Director & Managing Director<BR>2. Suninder Veer Singh - Executive Director & Wholetime Director<BR>3. Arshdeep Kaur - Independent Non-Executive Director<BR>4. Neena Batra - Non-Executive & Non-Independent Director<BR>5. Renu Rawat - Independent Non-Executive Director<BR><BR>These members play various roles within the company's board of directors.

What does Syschem (India) do?

Syschem (India) Ltd manufactures Active Pharmaceutical Ingredients (API) and intermediates in the Pharmaceuticals & Biotechnology sector. Incorporated in 1993, it reported net sales of 119 Cr and a net profit of 0 Cr for the quarter ending March 2025, with a market cap of Rs 207 Cr.

Overview:<BR>Syschem (India) Ltd is engaged in the manufacturing of Active Pharmaceutical Ingredients (API) and intermediates, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap company.<BR><BR>History:<BR>Incorporated in 1993, Syschem (India) was formerly known as Anil Pesticides Limited. The company launched its first product, Monocrotophos, in 1996, with production commencing in 1998. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 119 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 0 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: Rs 207 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 204.00<BR>- Industry P/E: 47<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.02<BR>- Return on Equity: 0.50%<BR>- Price to Book: 2.24<BR><BR>Contact Details:<BR>Address: Tehsil Kalka, Bargodam Village Panchkula Haryana : 133302<BR>Tel: 91-172-3077777<BR>Email: info@syschem.in<BR>Website: http://www.syschem.in

Has Syschem (India) declared dividend?

No Dividend History Available

Who are the peers of the Syschem (India)?

Syschem (India) peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Panch. Organics, Murae Organisor, Bafna Pharma, and Krebs Biochem. Syschem has below-average management risk and growth, with a 1-year return of -2.71%.

Peers: The peers of Syschem (India) are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Panch.Organics, Murae Organisor, Bafna Pharma., and Krebs Biochem.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Average management risk is found at Panch.Organics, Syschem (India), Murae Organisor, Bafna Pharma., and the rest. Below Average management risk is noted for Syschem (India), Murae Organisor, and Bafna Pharma. Growth is Excellent for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Murae Organisor, while Average growth is seen at Syschem (India) and Good growth at Bafna Pharma. Below Average growth is reported for Divi's Lab., Torrent Pharma, and Panch.Organics. Capital Structure is Excellent for Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, and Panch.Organics, while Average is noted for Syschem (India) and Below Average for Murae Organisor.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.69%, while Bafna Pharma. has the lowest at -11.19%. Syschem (India) has a 1-year return of -2.71%, which is better than Bafna Pharma. but significantly lower than Divi's Lab. Additionally, Panch.Organics, Krebs Biochem, and Amwill have negative six-month returns.

What is the technical trend for Syschem (India)?

As of May 12, 2025, Syschem (India) shows a mildly bearish trend with mixed signals from key indicators, including a mildly bullish weekly MACD and a mildly bearish monthly MACD, suggesting a lack of strong momentum.

As of 12 May 2025, the technical trend for Syschem (India) has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD is mildly bearish, indicating mixed signals. The Bollinger Bands show a bullish stance on the weekly chart but are mildly bearish on the monthly chart. Moving averages on the daily timeframe are mildly bearish, suggesting short-term weakness. The KST is mildly bullish on the weekly and mildly bearish on the monthly, further contributing to the mixed outlook. Overall, the current technical stance is mildly bearish, with key indicators reflecting a lack of strong momentum in either direction.

Who are the top shareholders of the Syschem (India)?

The top shareholders of Syschem (India) include promoter Virendra Popatlal Shah with 10.43%, and Ashika Global Finance Private Limited as the largest public shareholder at 4.44%. Individual investors hold a combined 33.37%, with no pledged promoter holdings or mutual funds/foreign institutional investors involved.

The top shareholders of Syschem (India) include the promoters, with Virendra Popatlal Shah holding the highest individual stake at 10.43%. In terms of public shareholders, Ashika Global Finance Private Limited is the largest, owning 4.44%. Additionally, individual investors collectively hold 33.37% of the company's shares. Notably, there are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares.

Is Syschem (India) overvalued or undervalued?

As of August 6, 2025, Syschem (India) is considered very expensive with a PE ratio of 100.12 and low ROCE and ROE, indicating it is overvalued at its current price of 45.79 despite a recent positive stock performance.

As of 6 August 2025, the valuation grade for Syschem (India) has moved from expensive to very expensive. The company is currently overvalued, with a PE ratio of 100.12, an EV to EBITDA of 34.95, and a PEG ratio of 2.03. In comparison, peers such as Solar Industries and Gujarat Fluoroch are also categorized as very expensive, with PE ratios of 112.38 and 64.46, respectively, highlighting that Syschem's valuation is not an outlier in the industry but remains significantly high.<BR><BR>Despite the recent stock performance showing a 3.93% return over the past week compared to a -1.15% return for the Sensex, the overall valuation metrics indicate that Syschem (India) is not justified at its current price of 45.79. The low ROCE of 1.16% and ROE of 2.18% further emphasize the disconnect between its market price and fundamental performance, reinforcing the conclusion that the stock is overvalued.

How has been the historical performance of Syschem (India)?

Syschem (India) has shown significant sales growth, increasing from 59.00 Cr in Mar'22 to 331.68 Cr in Mar'25, but profitability has declined, with profit after tax dropping from 4.51 Cr in Mar'23 to 0.46 Cr in Mar'25, and cash flow from operations remains negative. Total assets and liabilities grew in tandem, indicating financial challenges despite overall growth.

Answer:<BR>The historical performance of Syschem (India) shows significant fluctuations in key financial metrics over the years, particularly in net sales, operating profit, and profit after tax.<BR><BR>Breakdown:<BR>Syschem (India) has experienced a notable increase in net sales, rising from 59.00 Cr in Mar'22 to 331.68 Cr in Mar'25, reflecting a strong growth trajectory. Total operating income followed a similar trend, reaching 331.68 Cr in Mar'25, up from 59.00 Cr in Mar'22. However, the company's total expenditure also increased significantly, from 58.44 Cr in Mar'22 to 327.69 Cr in Mar'25, primarily driven by rising raw material costs, which surged from 46.97 Cr in Mar'22 to 310.87 Cr in Mar'25. Operating profit (PBDIT) showed volatility, peaking at 8.90 Cr in Mar'23 but dropping to 4.03 Cr in Mar'25. Profit before tax also fluctuated, with a high of 6.15 Cr in Mar'23 and a decline to 1.01 Cr in Mar'25. Profit after tax mirrored this trend, decreasing from 4.51 Cr in Mar'23 to 0.46 Cr in Mar'25. The company's total assets grew from 55.87 Cr in Mar'22 to 216.87 Cr in Mar'25, while total liabilities increased from 55.87 Cr to 216.87 Cr in the same period. Cash flow from operating activities remained negative, indicating ongoing challenges in generating cash from core operations, although cash flow from financing activities showed improvement, contributing to a net cash inflow of 2.00 Cr in Mar'25. Overall, Syschem (India) has shown growth in sales and assets, but profitability and cash flow remain areas of concern.

Are Syschem (India) Ltd latest results good or bad?

Syschem (India) Ltd's latest results are very positive, with net sales up 81.97% year-on-year and net profit soaring 734%. However, the stock's high price-to-earnings ratio of 50x raises concerns about sustainability.

Syschem (India) Ltd's latest results can be characterized as very positive. In the third quarter of FY26, the company reported net sales of ₹141.50 crores, reflecting an impressive year-on-year growth of 81.97% and a quarter-on-quarter increase of 36.58%. This strong revenue growth is complemented by a significant improvement in profitability, with net profit soaring to ₹4.17 crores, marking a staggering 734% increase compared to the same quarter last year and a 119.47% rise from the previous quarter.<BR><BR>The operating margin reached an all-time high of 4.21%, showcasing the company's operational efficiency and effective cost management. Additionally, the profit after tax (PAT) margin expanded to 2.95%, indicating a solid trend in profitability.<BR><BR>Despite these strong results, it's important to note that Syschem's stock trades at a high price-to-earnings ratio of approximately 50x, which is above the pharmaceutical sector average of 39x. This raises some questions about the sustainability of such high valuations moving forward.<BR><BR>Overall, the financial performance reflects a robust growth trajectory, but potential investors should consider the elevated valuation levels and the associated risks.

Should I buy, sell or hold Syschem (India) Ltd?

Why is Syschem (India) Ltd falling/rising?

As of 16-Mar, Syschem (India) Ltd's stock price is at 45.55, reflecting a decline of 1.73% and underperforming its sector. The stock has decreased by 10.00% over the past month and is trading below all key moving averages, indicating a bearish trend despite a rise in investor participation.

As of 16-Mar, Syschem (India) Ltd's stock price is falling, currently at 45.55, which reflects a decrease of 0.8 or 1.73%. This decline is evident in today's performance, where the stock underperformed its sector by 0.92%. Additionally, Syschem is trading lower than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend.<BR><BR>Over the past month, the stock has decreased by 10.00%, while the benchmark Sensex has only fallen by 9.34%, suggesting that Syschem is lagging behind the broader market. Year-to-date, the stock has seen a slight decline of 2.57%, compared to a more significant drop of 11.40% in the Sensex, which indicates some relative strength but still reflects a negative trend.<BR><BR>Despite these challenges, there has been a rise in investor participation, with a delivery volume increase of 13.12% on March 13 compared to the 5-day average. However, this increase in participation has not translated into a positive price movement, as the overall performance remains negative. Thus, the combination of underperformance against benchmarks, trading below moving averages, and a recent price decline contributes to the current falling trend of Syschem (India) Ltd's stock price.

Which are the latest news on Syschem (India)?